Several pivotal phase III clinical trials have been performed in patients with advanced gastric cancer, including the V325 study of docetaxel plus cisplatin/5-fluorouracil by the V325 Study Group (Van Cutsem et al. 2006), a randomized trial of epirubicin plus cisplatin/5-fluorouracil by Cunningham and co-workers (Webb et al. 1997; Waters et al. 1999; Ross et al. 2002), and the SPIRITS trial of S-1 plus cisplatin by the SPRITS Trial Group (Koizumi et al. 2008). The gene discussed is PSMD1; the disease is gastric cancer.